Health
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC – MedPage Today
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Neoadjuvant combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) produced a significant clinical benefit for patients with operable stage I-III non-small cell lung cancer (NSCLC), researchers reported.
The phase II NEOSTAR study randomly assigned 44 patients with operable NSCLC to neoadjuvant nivolumab with or without ipilimumab followed by surgery. Among those, 38% of patients that received the combination achieved major pathological response (MPR) — defined as 10% or less…
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business23 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
Noosa News22 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers